Literature DB >> 15893068

Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs.

Jacqueline Poot1, Matthew E Rogers, Paul A Bates, Arno Vermeulen.   

Abstract

In this study, disease progression after intravenous or subdermal infection of dogs with Leishmania infantum JPC strain was monitored. A challenge performed on 14 dogs via the intravenous route with 5 x 10(7) stationary phase promastigotes of the L. infantum JPC strain was 100% successful. During a follow up period of 1.5 years, several parameters were evaluated in order to find the most reliable disease markers. Parasite detection by culture and histology were found to be very sensitive (100%). Additionally, regular physical examination, serology and serum gamma-globulin levels were found to be useful parameters in the evaluation of disease severity and are recommended for inclusion in vaccination-challenge experiments. Although this intravenous challenge model has practical limitations, the data set confirms it is the best experimental model currently available for vaccine development. Two intravenously infected dogs were treated with corticosteroids for 5 months. This treatment was shown to enhance all aspects of a Leishmania infection. Five more dogs were infected by sub-dermal injection of promastigotes mixed with a proteophosphoglycan-matrix (PSG) secreted by Leishmania that assists in transmission and infection by sand fly bite. The resulting parasite burdens were low and the animals remained asymptomatic during a 2-year follow up period. However, this procedure did result in infection in 80% of the dogs and is appealing for future development as a natural challenge model in vaccine development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893068     DOI: 10.1016/j.vetpar.2005.03.002

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  13 in total

1.  Immunohistochemical study of renal fibropoiesis associated with dogs naturally and experimentally infected with two different strains of Leishmania (L.) infantum.

Authors:  Adriano F Alves; Ramon A Pereira; Helida M de Andrade; David M Mosser; Wagner L Tafuri
Journal:  Int J Exp Pathol       Date:  2019-11-06       Impact factor: 1.925

2.  Immunogenicity in dogs and protection against visceral leishmaniasis induced by a 14kDa Leishmania infantum recombinant polypeptide.

Authors:  Claudia Abeijon; Nada Daifalla; Greice Krautz-Peterson; Stefano Pizzirani; Gillian Beamer; Neuza M Frazatti-Gallina; Isaias Raw; Antonio Campos-Neto
Journal:  Trials Vaccinol       Date:  2016

3.  The effect of phospholipase A2 from Crotalus durissus collilineatus on Leishmania (Leishmania) amazonensis infection.

Authors:  Luiz Felipe Domingues Passero; Márcia Dalastra Laurenti; Thaise Y Tomokane; Carlos Eduardo P Corbett; Marcos H Toyama
Journal:  Parasitol Res       Date:  2008-01-08       Impact factor: 2.289

4.  Studies on the CPA cysteine peptidase in the Leishmania infantum genome strain JPCM5.

Authors:  Hubert Denise; Jacqueline Poot; Maribel Jiménez; Audrey Ambit; Daland C Herrmann; Arno N Vermeulen; Graham H Coombs; Jeremy C Mottram
Journal:  BMC Mol Biol       Date:  2006-11-13       Impact factor: 2.946

5.  Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.

Authors:  Laura Manna; Raffaele Corso; Giorgio Galiero; Anna Cerrone; Paolo Muzj; Angelo Elio Gravino
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

6.  Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs.

Authors:  Ryuichi Miura; Takanori Kooriyama; Misako Yoneda; Akiko Takenaka; Miho Doki; Yasuyuki Goto; Chizu Sanjoba; Yasuyuki Endo; Tomoko Fujiyuki; Akihiro Sugai; Kyoko Tsukiyama-Kohara; Yoshitsugu Matsumoto; Hiroki Sato; Chieko Kai
Journal:  PLoS Negl Trop Dis       Date:  2015-07-10

7.  LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Henrique Gama Ker; Nádia das Dores Moreira; Fernando Augusto Siqueira Mathias; Jamille Mirelle de Oliveira Cardoso; Nelder Figueiredo Gontijo; Oscar Bruna-Romero; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Parasit Vectors       Date:  2014-02-07       Impact factor: 3.876

8.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

9.  The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.

Authors:  Virginie Martin; Ioannis Vouldoukis; Javier Moreno; David McGahie; Sylvie Gueguen; Anne-Marie Cuisinier
Journal:  Vet Res       Date:  2014-06-25       Impact factor: 3.683

10.  A canine model of experimental infection with Leishmania (L.) mexicana.

Authors:  Julio Vladimir Cruz-Chan; Amarú del Carmen Aguilar-Cetina; Liliana Estefanía Villanueva-Lizama; Pedro Pablo Martínez-Vega; Maria Jesús Ramírez-Sierra; Miguel Enrique Rosado-Vallado; José Leonardo Guillermo-Cordero; Eric Dumonteil
Journal:  Parasit Vectors       Date:  2014-08-09       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.